Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1026 phase 2 study in relapsed or refractory hematologic malignancies
2023-504931-42-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 2, open-label trial of nemtabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Richter's syndrome (RS), mantle cell lymphoma (MCL) and 3 more (10 arms), sponsored by Merck & Co. Primary endpoints: Number of participants experiencing dose-limiting toxicities, Number of participants experiencing adverse events and 4 more. Planned start Dec 2023; status: authorised.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Richter's syndrome (RS)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-504931-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504931-42-00.